The clinical value of new tumor biomarker cytokeratin 2g2 detection in non-small cell lung cancer patients

Clinical Laboratory

Volumn 59, Issue 5-6, 2013, Pages 551-556

  Liang, Zi Kun ^a   Yin, Yan Jun ^a   Wu, En Dong ^a   Shi, Guang Li ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Chemotherapy; Diagnosis; Lung cancer; Tumor marker

Indexed keywords

CYTOKERATIN;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER REGRESSION; CANCER SIZE; CANCER STAGING; CHEMOLUMINESCENCE; CONTROLLED STUDY; DISEASE MARKER; DISEASE SEVERITY; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CASE-CONTROL STUDIES; FEMALE; HUMANS; KERATIN-19; LUMINESCENT MEASUREMENTS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; ROC CURVE; SENSITIVITY AND SPECIFICITY; STATISTICS, NONPARAMETRIC; TUMOR MARKERS, BIOLOGICAL;

EID: 84879348163     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: 10.7754/Clin.Lab.2012.120511     Document Type: Article

References (33)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics. CA Cancer J Cln 2009;59:225-49.
2. Tiseo M, Ardizzoni A, Cafferata MA, et al. Predictive and prognostic significance of neuron-specific enolase (NSE) in Non-small cell lung cancer. Anticancer Res 2008;28:507-13. (Pubitemid 351362861)
3. Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology Treatment of Unresectable Non-Small-Cell Lung Cancer Guideline: update 2003. J Clin Oncol 2004;22:195-330.
4. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated on individual patients from 52 randomised clinical trials. Br Med J 1995;311:899-909.
5. Gridelli C, Rossi A, Maione P. Treatment of non-small-cell lung cancer: state of the art and development of new biologic agents. Oncogene 2003;22:6629-38. (Pubitemid 37372343)
6. Ebert W, Muley T. CYFRA21-1 in the follow-up of inoperable non-small cell lung cancer patients treated with chemotherapy. Anticancer Res 1999;19:2669-72. (Pubitemid 29392435)
7. Vander Gaast A, Kok TC. Disease monitoring by tumor markers cyfra21-1 and TPA in patients with non-small cell lung cancer. Eur J Cancer 1995;31A:1790-3.
8. Werner-Wasik M, Xiao Y, Pequignot E, Curran WJ, Hauck W. Assessment of lung cancer response after nonoperative therapy tumor diameter, bidimensional product, and volume. A serial CT scan-based study. Int J Radiat Oncol Biol Phys 2001;51:56-61. (Pubitemid 32758861)
9. Mizuguchi S, Nishiyama N, Iwata T, et al. Clinical value of serum cytokeratin 19 fragment and Sialyl-Lewis X in non-small cell lung cancer. Ann Thorac Surg 2007;216-21. (Pubitemid 44917907)
10. Ardizzoni A, Cafferata MA, Tiseo M, et al. Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced non-small cell lung cancer. Cancer 2006;107:2842-9. (Pubitemid 44937038)
11. Trape J, Buxo J, Perez de Olaguer J, Vidal C. Tumor markers as prognostic factors in treated non-small cell lung cancer. Anti-cancer Res 2003;23:4277-81. (Pubitemid 37474933)
12. Buccheri G, Ferrigno D. Lung tumor markers in onlogy practice:A study of TPA and CA125. Br J Cancer 2002;87:112-8.
13. Hatzakis KD, Froudarakis ME, Bouros D, Tzanakis N, Karkavitsas N, Siafakas NM. Prognostic value of serum tumor markers in patients with lung cancer. Respiration 2002;69:9-25.
14. Holdenrieder S, Stieber P, Von Pawel J, Raith H, Nagel D, Feldmann K. Early and specific prediction of therapeutic efficacy in non-small cell lung cancer patients by nucleosomal DNA and cytokeratin-19 fragment. Ann NY Acad Sci 2006;1075:244-57. (Pubitemid 44532791)
15. Niklinski J, Burzykowski T, Niklinska W, et al. Preoperative CY FRA21-1 level as a prognostic indicator in resected non-small cell lung cancer. Eur Respir J 1998;12:1424-8. (Pubitemid 29011441)
16. Pujol JL, Molinier O, Ebert W, et al. CYFRA21-1 is a prognostic determinant in non-small cell lung cancer: results of a meta-analysis in 2063 patients. Br J Cancer 2004;90:2097-105. (Pubitemid 38869712)
17. Mizuguchi S, Inoue K, Iwata T, et al. High serum concentrations of Sialyl-Lewis(x) predict multilevel N2 disease in non-small cell lung cancer. Ann Surg Oncol 2006;13:1008-10.
18. Sugama Y, Kitamura S, Kawai T, et al. Clinical usefulness of CYFRA assay in diagnosing lung cancer: measurement of serum cytokeratin fragment. Jpn J Cancer Res 1994;85:1178-84. (Pubitemid 24356092)
19. Brechot JM, Chevret S, Nataf J. Le Gall C, Fretault J, Chastang C. Diagnostic and prognostic value of CYFRA21-1 compared with other tumor markers in patients with non-small cell lung cancer: a prospective study of 116 patients. Eur J Cancer 1997;33:385-91. (Pubitemid 27168063)
20. Gautschi O, Bigosch C, Huegli B, et al. Circulating deoxyribonucleic acid as prognostic marker in non-small-cell lung cancer patients undergoing chemotherapy. J Clin Oncol 2004;22:4157-64. (Pubitemid 41185186)
21. Watine J, Friedberg B, Bouarioua N. Biological variables and stratification of patients with inoperable non-small-cell bronchial cancer: recommendations for future trials. Cancer Radiother 2002;6:209-16.
22. Yamamoto K, Oka M, Hayashi H, Tangoku A, Gondo T, Suzuki T. CYFRA21-1 is a useful marker for esophageal squamous cell carcinoma. Cancer 1997;79:1647-55. (Pubitemid 27176344)
23. Ohno T, Nakayama Y, Nakamoto S, et al. Measurement of serum squamous cell carcinoma antigen levels as a predictor of radiation response in patients with carcinoma of the uterine cervix. Cancer 2003;97:3114-20. (Pubitemid 36676268)
24. de Castro J, Rodríguez MC, Martínez-Zorzano VS, Hernández-Hernández A, Llanillo M, Sánchez-Yagüe J. Erythrocyte and platelet phospholipid fatty acids as markers of advanced non-small cell lung cancer: comparison with serum levels of sialic acid, TPS and Cyfra21-1. Cancer Investing 2008;26:407-18. (Pubitemid 351601401)
25. Buccheri G, Ferrigno D. Lung tumor markers of cytokeratin origin: an overview. Lung Cancer 2001;34 Suppl 2:S65-9. (Pubitemid 33101848)
26. Fischer JR, Lahm H. Validation of molecular and immunological factors with predictive importance in lung cancer. Lung Cancer 2004;45 Suppl 2:S151-161. (Pubitemid 39488185)
27. Nagler RM, Barak M, Peled M, Ben-Aryeh H, Filatov M, Laufer D. Early diagnosis and treatment monitoring roles of tumor markers cyfra21-1 and TPS in oral squamous cell carcinoma. Cancer 1999;85:1018-25. (Pubitemid 29115578)
28. Zissimopoulos A, Stellos K, Permenopoulou V, et al.The importance of the tumor marker CYFRA21-1 in patients with lung cancer after surgery or chemotherapy. Hell J Nucl Med 2007;10:62-6. (Pubitemid 46692254)
29. Vollmer RT, Govindan R, Graziano SL, et al. Serum CYFRA21-1 in advanced stage non-small cell lung cancer: an early measure of response. Clin Cancer Res 2003;9:1728-33. (Pubitemid 36554597)
30. Lai R, Hsu H, Lu JY, Ger LP, Lai NS. CYFRA21-1 enzyme-linked immunosorbent assay. Chest 1996;109:995-1000.
31. Brenmes RM, Sirera R, Camps C. Circulating tumor-derived DNA and RNA markers in blood: a tool for early detection, diagnostics, and follow-up? Lung Cancer 2005;49:1-12. (Pubitemid 40798088)
32. Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006;355:983-91. (Pubitemid 44343542)
33. Goekkurt E, Hoehn S, Wolschke C, et al. Polymorphisms of glutathiones-transferases (GST) and thymidylate synthase (TS) -novel predictors for response and survival in gastric cancer patients. Br J Cancer 2006;94:281-6. (Pubitemid 43151548)